Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sprint Bioscience AB (OSTO:SPRINT) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sprint Bioscience AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr142.8 Mil.
Sprint Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr90.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB EV-to-EBIT Related Terms
Sprint Bioscience AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's EV-to-EBIT falls into.
Sprint Bioscience AB's current Enterprise Value is kr271.5 Mil.
Sprint Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr90.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a EV-to-EBIT of 3.02 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #130 out of 387 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Sprint Bioscience AB's EV-to-EBIT too high?
Sprint Bioscience AB's current EV-to-EBIT is 3.02. The Biotechnology industry median EV-to-EBIT is 12.63. Sprint Bioscience AB's value of 3.02 is 76.1% below this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #130 out of 387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #130 out of 387 companies for EV-to-EBIT. This puts Sprint Bioscience AB in the upper half of its industry. The industry median EV-to-EBIT is 12.63. Sprint Bioscience AB's value of 3.02 is 76.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current EV-to-EBIT of 3.02 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current EV-to-EBIT is 3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (OSTO:SPRINT) has a current EV-to-EBIT of 3.02. The current EV-to-EBIT is 3.02 and 76.1% below the Biotechnology industry median of 12.63. Sprint Bioscience AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current EV-to-EBIT is 3.02 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
22GF Score
Get the complete analysis for OSTO:SPRINT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
